mirtazapine has been researched along with fluoxetine in 85 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.18) | 18.7374 |
| 1990's | 11 (12.94) | 18.2507 |
| 2000's | 34 (40.00) | 29.6817 |
| 2010's | 33 (38.82) | 24.3611 |
| 2020's | 6 (7.06) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Cortizo, L; García, N; Innerárity, A; Labeaga, L; Mosquera, R; Orjales, A; Pumar, MC; Toledo, A | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Buck, LB; Petrascheck, M; Ye, X | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Claxton, CR; Curran, RE; Harradine, PJ; Hutchison, L; Littlewood, P; Martin, IJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Alix, K; Dukat, M; Khatri, S; Schulte, MK; Worsham, J | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Smith, DF | 1 |
| Berendsen, HH; Broekkamp, CL | 1 |
| Pinder, RM | 1 |
| Kremer, CM; Timmerman, L; van Moffaert, M; Wheatley, DP | 1 |
| Benazzi, F | 1 |
| Farah, A | 1 |
| Montgomery, SA | 1 |
| Thompson, C | 1 |
| Nutt, DJ | 1 |
| Thase, ME | 1 |
| Brown, MC; Guest, JF; Nimmerrichter, AA | 1 |
| Häggström, L; Nordling, S; Norinder, A | 1 |
| Borghi, J; Guest, JF | 1 |
| Gorman, JM; Nierenberg, AA; Stahl, SM | 1 |
| Kremer, C; Quitkin, FM; Taylor, BP | 1 |
| Nierenberg, AA | 1 |
| Busnello, EA; Busnello, JV; Kapczinski, F; Kauer-Sant'Anna, M; Madruga, M; Quevedo, J; Ribeiro, L | 1 |
| Ng, B | 1 |
| Bouvard, M; Rénéric, JP; Stinus, L | 2 |
| Biggio, G; Dazzi, L; Pisul, MG; Purdy, RH; Serra, M | 1 |
| Lima, L; Urbina, M | 1 |
| Chen, CC; Hong, CJ; Hsiao, CC; Hu, WH; Ruwe, FJ; Tsai, SJ | 1 |
| Cormier, JL; DeMartinis, NA; Gary, EM; Gary, KA; McNally, DP; Winokur, A | 1 |
| Drobizhev, MIu; Kozyrev, VN; Kraeva, GK; Kubrakov, MA; Smulevich, AB | 1 |
| Bateman, DN; Chick, J; Good, AM; Kelly, CA; Masterton, G | 1 |
| Norman, TR; Olver, JS | 1 |
| Lawrence, RW | 1 |
| Moreno, R; Ramakers-van Moorsel, CJ; Schutte, AJ; Versiani, M | 1 |
| Aghayan, S; Akhondzadeh, S; Amini, H; Jalili, SA; Pakravan-Nejad, M; Yahyazadeh, O | 1 |
| Cela, R; Garcia-Jares, C; Lamas, JP; Llompart, M; Salgado-Petinal, C | 1 |
| Lambert, WE; Maudens, KE; Van Peteghem, CH; Wille, SM | 1 |
| Albertazzi, P | 1 |
| Fountoulakis, KN; Iacovides, A; Kaprinis, GS; Koumaris, V; Siamouli, M | 1 |
| Arana-Lechuga, Y; Prospero-Garcia, KA; Ramirez-Bermudez, J; Teran-Perez, G; Torres-Ruiz, A; Velazquez-Moctezuma, J | 1 |
| Connor, K; Davidson, JR; Vaishnavi, S | 1 |
| Olivier, B; Schweitzer, DH; Waldinger, MD; Zwinderman, AH | 1 |
| Liang, KY; Liao, SC; Liu, CC | 1 |
| Jia, L; Li, YY; Shang, YY | 1 |
| Bergeron, R; Blier, P; Hébert, C; Laberge, L; Tremblay, P; Ward, HE | 1 |
| Rush, AJ | 1 |
| Beauclair, L; Desmarais, JE; Margolese, HC; Wolf, Y | 1 |
| Nierenberg, AA; Schutte, AJ; Simmons, JH; Thase, ME; van Oers, HJ; Vrijland, P | 1 |
| Agius, M; Gardner, J; Liu, K; Zaman, R | 1 |
| Fonseca, C; Laino, CH; Reinés, A; Slobodianik, N; Sterin-Speziale, N | 1 |
| Fisar, Z; Hroudová, J; Raboch, J | 1 |
| Iwamura, T; Kasai, M; Kato, S; Nisijima, K; Shioda, K; Yoshino, T | 1 |
| Cabral, A; Ferreira, LS; Izídio, GS; Macedo, PT; Melo, TG; Ribeiro, AM; Silva, RH; Sousa, DS | 1 |
| Johansen, SS; Nielsen, MK | 1 |
| Fan, DS; Guo, L; Ji, CX; Li, W; Liang, ZL; Xu, RM; Zhang, JJ | 1 |
| Arterburn, D; Bogart, A; Boudreau, DM; Haneuse, S; Simon, G; Theis, MK; Westbrook, E | 1 |
| Gądek-Michalska, A; Kabziński, M; Rachwalska, P; Rogóż, Z; Sadaj, W | 1 |
| Clarke, G; Cryan, JF; Dinan, TG; Griffin, BT; O'Brien, FE | 1 |
| Arteta, B; Basta-Kaim, A; Budziszewska, B; Curzytek, K; Duda, W; Grygier, B; Kubera, M; Lasoń, W; Leśkiewicz, M; Maes, M | 1 |
| Purslow, C | 1 |
| Abe, M; Mori, Y; Nakata, S; Ochi, S; Ueno, S; Yamazaki, K; Yoshino, Y | 1 |
| Andersson, SI; Broaddus, CD; Gomez-Amaro, RL; Kardakaris, R; Niculescu, AB; Petrascheck, M; Rangaraju, S; Solis, GM | 1 |
| García-Fuster, MJ; García-Sevilla, JA | 1 |
| Cipriani, A; Coghill, D; Cohen, D; Cuijpers, P; Del Giovane, C; Hazell, P; Hetrick, SE; Leucht, S; Liu, L; Liu, Y; Michael, KD; Pu, J; Qin, B; Ravindran, AV; Whittington, C; Xie, P; Yang, L; Zhang, Y; Zhou, X | 1 |
| Kamińska, K; Pańczyszyn-Trzewik, P; Rogóż, Z; Sowa-Kućma, M | 1 |
| Bahar, MA; Bos, JHJ; Hak, E; Wang, Y; Wilffert, B | 1 |
| Carleton, BC; Etminan, M; Guo, MY; Kezouh, A; Kim, DD; Procyshyn, RM; Samii, A | 1 |
| Feng, S; Gu, J; Jiang, X; Tang, S; Wang, L; Zheng, L | 1 |
| Bacon, F; Clarke, CS; Donkor, Y; Duffy, L; Freemantle, N; Gilbody, S; Hunter, R; Kendrick, T; Kessler, D; King, M; Lanham, P; Lewis, G; Mangin, D; Marston, L; Moore, M; Nazareth, I; Wiles, N | 1 |
| Cen, M; Dai, N; Du, L; Luo, L; Shen, J | 1 |
| Chen, C; Shan, W | 1 |
| Badcock, PB; Bailey, AP; Cox, GR; Hetrick, SE; McKenzie, JE; Meader, N; Merry, SN; Moller, CI; Sharma, V | 1 |
| Koziorowski, M; Mytych, J; Sołek, P; Tabęcka-Łonczyńska, A | 1 |
| Hatano, M; Ikuta, T; Iwata, N; Kishi, T; Matsuda, Y; Okuya, M; Sakuma, K | 1 |
| Arteta, B; Curzytek, K; Grygier, B; Kubera, M; Maes, M; Malicki, S | 1 |
| Keidan, L; Pick, CG; Schreiber, S | 1 |
| Chen, L; Fan, H; Hu, Q; Li, K; Liu, X; Shi, Y; Wu, K; Zhong, J; Zhou, J | 1 |
16 review(s) available for mirtazapine and fluoxetine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
New developments in the treatment of depression.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Depressive Disorder; Fluoxetine; Humans; Mianserin; Mirtazapine; Placebos; Severity of Illness Index; Treatment Outcome | 1999 |
Mirtazapine versus selective serotonin reuptake inhibitors.
Topics: Antidepressive Agents, Tricyclic; Citalopram; Clinical Trials as Topic; Depressive Disorder; Fluoxetine; Humans; Mianserin; Mirtazapine; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1999 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidity; Depressive Disorder; Fluoxetine; Humans; Mianserin; Mirtazapine; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1999 |
Antidepressant treatment of the depressed patient with insomnia.
Topics: Antidepressive Agents, Tricyclic; Comorbidity; Cyclohexanols; Depressive Disorder; Fluoxetine; Humans; Mianserin; Mirtazapine; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Sleep; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride | 1999 |
Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in austria.
Topics: Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Austria; Cost-Benefit Analysis; Depressive Disorder; Double-Blind Method; Drug Hypersensitivity; Fluoxetine; Humans; Mianserin; Mirtazapine; Retrospective Studies; Severity of Illness Index | 1999 |
[Treatment of depression and cost efficiency. The cost of a tablet is a poor indicator seen from a socioeconomic perspective].
Topics: Adrenergic alpha-Agonists; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cost of Illness; Cost-Benefit Analysis; Depression; Drug Costs; Fluoxetine; Histamine H1 Antagonists; Humans; Mianserin; Mirtazapine; Models, Economic; Socioeconomic Factors; Sweden | 2000 |
Evidence of early onset of antidepressant effect in randomized controlled trials.
Topics: Antidepressive Agents; Citalopram; Cyclohexanols; Depressive Disorder; Drug Administration Schedule; Fluoxetine; Humans; Mianserin; Mirtazapine; Personality Inventory; Placebos; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2001 |
Do some antidepressants work faster than others?
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Controlled Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Fluoxetine; Humans; Mianserin; Mirtazapine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2001 |
New formulations of existing antidepressants: advantages in the management of depression.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Chemistry, Pharmaceutical; Cyclohexanols; Delayed-Action Preparations; Depression; Drug Evaluation; Fluoxetine; Humans; Mianserin; Mirtazapine; Molecular Conformation; Venlafaxine Hydrochloride | 2004 |
Noradrenergic and serotonergic modulation to treat vasomotor symptoms.
Topics: Citalopram; Cyclohexanols; Female; Fluoxetine; Hot Flashes; Humans; Menopause; Mianserin; Mirtazapine; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Trazodone; Venlafaxine Hydrochloride | 2006 |
Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Citalopram; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Fluvoxamine; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Patient Dropouts; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Young Adult | 2010 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Confounding Factors, Epidemiologic; Depressive Disorder, Major; Desipramine; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Evidence-Based Medicine; Fluoxetine; Humans; Imipramine; Mianserin; Mirtazapine; Nortriptyline; Paroxetine; Piperazines; Randomized Controlled Trials as Topic; Research Design; Sertraline; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride | 2016 |
Pharmacological and non-pharmacological treatments for major depressive disorder in adults: A systematic review and network meta-analysis.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Bupropion; Cognitive Behavioral Therapy; Depressive Disorder, Major; Fluoxetine; Humans; Mirtazapine; Network Meta-Analysis; Treatment Outcome; Venlafaxine Hydrochloride; Vortioxetine | 2019 |
New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Topics: Adolescent; Antidepressive Agents; Bias; Child; Citalopram; Depressive Disorder, Major; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Mirtazapine; Network Meta-Analysis; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Suicidal Ideation; Venlafaxine Hydrochloride; Vilazodone Hydrochloride; Vortioxetine | 2021 |
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Topics: Adult; Amitriptyline; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Female; Fluoxetine; Fluvoxamine; Humans; Mirtazapine; Network Meta-Analysis; Paroxetine; Randomized Controlled Trials as Topic; Reboxetine; Sertraline; Venlafaxine Hydrochloride; Vortioxetine | 2023 |
11 trial(s) available for mirtazapine and fluoxetine
| Article | Year |
|---|---|
Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Depressive Disorder; Drug Administration Schedule; Female; Fluoxetine; Headache; Health Status; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Nausea; Psychiatric Status Rating Scales; Quality of Life; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Sleep | 1998 |
Relief of SSRI-induced sexual dysfunction with mirtazapine treatment.
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety Disorders; Drug Therapy, Combination; Female; Fluoxetine; Humans; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Sexual Dysfunctions, Psychological; Treatment Outcome | 1999 |
Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in austria.
Topics: Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Austria; Cost-Benefit Analysis; Depressive Disorder; Double-Blind Method; Drug Hypersensitivity; Fluoxetine; Humans; Mianserin; Mirtazapine; Retrospective Studies; Severity of Illness Index | 1999 |
Mirtazapine versus fluoxetine in the treatment of panic disorder.
Topics: Adolescent; Adult; Analysis of Variance; Antidepressive Agents, Tricyclic; Double-Blind Method; Female; Fluoxetine; Humans; Male; Mianserin; Mirtazapine; Panic Disorder; Selective Serotonin Reuptake Inhibitors | 2001 |
A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents, Tricyclic; Depressive Disorder; Double-Blind Method; Ethnicity; Female; Fluoxetine; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Taiwan; Treatment Outcome | 2003 |
Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluoxetine; Follow-Up Studies; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Polysomnography; Sleep Initiation and Maintenance Disorders; Treatment Outcome | 2003 |
Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Female; Fluoxetine; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Personality Inventory; Psychiatric Status Rating Scales; Time Factors; Treatment Outcome | 2005 |
Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial.
Topics: Adolescent; Adult; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Administration Schedule; Female; Fluoxetine; Humans; Inpatients; Male; Mianserin; Middle Aged; Mirtazapine; Outpatients; Oxazepam; Treatment Outcome | 2005 |
Fluoxetine-mirtazapine interaction may induce restless legs syndrome: report of 3 cases from a clinical trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Drug Interactions; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Restless Legs Syndrome; Sleep Initiation and Maintenance Disorders | 2006 |
Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.
Topics: Adult; Antidepressive Agents; Bupropion; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Personality Inventory; Psychometrics; Secondary Prevention; Venlafaxine Hydrochloride | 2010 |
A randomised controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants to prevent reLapse in dEpRes
Topics: Adult; Aged; Antidepressive Agents; Citalopram; Cost-Benefit Analysis; Depression; Double-Blind Method; Fluoxetine; Humans; Middle Aged; Mirtazapine; Outcome Assessment, Health Care; Primary Health Care; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Sample Size; Sertraline | 2019 |
59 other study(ies) available for mirtazapine and fluoxetine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Brain; Carrier Proteins; Fluoxetine; In Vitro Techniques; Male; Membrane Glycoproteins; Membrane Transport Proteins; Morpholines; Nerve Tissue Proteins; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Piperidines; Radioligand Assay; Rats; Rats, Wistar; Reboxetine; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Stereoisomerism; Structure-Activity Relationship; Symporters | 2003 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
Topics: Aging; Animals; Antidepressive Agents; Caenorhabditis elegans; Caloric Restriction; Humans; Longevity; Methiothepin; Mianserin; Octopamine; Receptors, Biogenic Amine; Receptors, Serotonin, 5-HT4; Serotonin; Serotonin 5-HT4 Receptor Antagonists; Serotonin Antagonists; Signal Transduction; Starvation | 2007 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
Topics: Animals; Blood Proteins; Buffers; Carbon Dioxide; Chemical Phenomena; Dialysis; Dogs; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Macaca fascicularis; Mice; Osmolar Concentration; Pharmaceutical Preparations; Protein Binding; Rats; Reproducibility of Results | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
2-Amino-6-chloro-3,4-dihydroquinazoline: A novel 5-HT3 receptor antagonist with antidepressant character.
Topics: Amination; Animals; Antidepressive Agents; Anura; Halogenation; Hindlimb Suspension; Mice; Quinazolines; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists | 2013 |
The stereoselectivity of serotonin uptake in brain tissue and blood platelets: the topography of the serotonin uptake area.
Topics: Alanine; Amphetamine; Aniline Compounds; Animals; Antidepressive Agents; Blood Platelets; Brain; Fluoxetine; Humans; Male; Methadone; Mianserin; Mirtazapine; Morpholines; Naphthalenes; Nefopam; Nomifensine; Paroxetine; Piperidines; Rabbits; Serotonin; Stereoisomerism; Tranylcypromine; Viloxazine; Zimeldine | 1986 |
Indirect in vivo 5-HT1A-agonistic effects of the new antidepressant mirtazapine.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amphetamines; Animals; Antidepressive Agents, Tricyclic; Behavior, Animal; Conditioning, Operant; Fluoxetine; Male; Mianserin; Mice; Mice, Inbred ICR; Mirtazapine; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Taste | 1997 |
The pharmacologic rationale for the clinical use of antidepressants.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Clinical Trials as Topic; Depressive Disorder; Fluoxetine; Humans; Mianserin; Mirtazapine; Psychiatric Status Rating Scales; Receptors, Adrenergic; Receptors, Serotonin; Treatment Outcome | 1997 |
Serotonin syndrome with mirtazapine-fluoxetine combination.
Topics: Adrenergic alpha-Antagonists; Aged; Antidepressive Agents, Tricyclic; Depression; Drug Interactions; Drug Therapy, Combination; Female; Fluoxetine; Humans; Mianserin; Mirtazapine; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome | 1998 |
[Mirtazapin--fast and strong effects].
Topics: Antidepressive Agents, Tricyclic; Depression; Fluoxetine; Humans; Mianserin; Mirtazapine; Selective Serotonin Reuptake Inhibitors | 1998 |
Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amitriptyline; Antidepressive Agents, Tricyclic; Cost-Benefit Analysis; Depression; Fluoxetine; Humans; Mianserin; Middle Aged; Mirtazapine; Severity of Illness Index; United Kingdom | 2000 |
Does mirtazapine have a more rapid onset than SSRIs?
Topics: Antidepressive Agents, Tricyclic; Citalopram; Cross-Sectional Studies; Data Interpretation, Statistical; Depressive Disorder; Double-Blind Method; Fluoxetine; Humans; Mianserin; Mirtazapine; Paroxetine; Patient Dropouts; Placebo Effect; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Research Design; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2001 |
Mania associated with mirtazapine augmentation of fluoxetine.
Topics: Adrenergic alpha-Antagonists; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoxetine; Humans; Mianserin; Middle Aged; Mirtazapine; Selective Serotonin Reuptake Inhibitors; Time Factors | 2002 |
In the rat forced swimming test, NA-system mediated interactions may prevent the 5-HT properties of some subacute antidepressant treatments being expressed.
Topics: Adrenergic alpha-Antagonists; Animals; Antidepressive Agents; Biogenic Monoamines; Brain; Depression; Dopamine Agents; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Immobilization; Male; Mianserin; Mirtazapine; Motor Activity; Norepinephrine; Oxidopamine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Swimming | 2002 |
Prevention of the stress-induced increase in the concentration of neuroactive steroids in rat brain by long-term administration of mirtazapine but not of fluoxetine.
Topics: Adrenergic alpha-Antagonists; Animals; Antidepressive Agents, Second-Generation; Brain Chemistry; Cerebral Cortex; Chromatography, High Pressure Liquid; Desoxycorticosterone; Electroshock; Fluoxetine; Male; Mianserin; Mirtazapine; Pregnanolone; Rats; Rats, Sprague-Dawley; Receptors, GABA-A; Steroids; Stress, Psychological | 2002 |
In the rat forced swimming test, chronic but not subacute administration of dual 5-HT/NA antidepressant treatments may produce greater effects than selective drugs.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Clonidine; Cyclopropanes; Depression; Desipramine; Dose-Response Relationship, Drug; Drug Synergism; Fluoxetine; Male; Mianserin; Milnacipran; Mirtazapine; Motor Activity; Norepinephrine; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Selective Serotonin Reuptake Inhibitors; Swimming | 2002 |
Serotonin transporter modulation in blood lymphocytes from patients with major depression.
Topics: Adrenergic alpha-Antagonists; Adult; Antidepressive Agents, Second-Generation; Brain; Carrier Proteins; Depressive Disorder, Major; Down-Regulation; Female; Fluoxetine; Humans; Lymphocytes; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mianserin; Mirtazapine; Nerve Tissue Proteins; Neuroimmunomodulation; Paroxetine; Radioligand Assay; Serotonin; Serotonin Plasma Membrane Transport Proteins; Treatment Outcome; Up-Regulation | 2002 |
[Psychotropic drugs used in a psychiatric hospital (pharmaco-epidemiologic aspects)].
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Carbazoles; Chlorprothixene; Clopenthixol; Data Collection; Dopamine Antagonists; Female; Fluoxetine; Flupenthixol; Hospitals, Psychiatric; Humans; Male; Mental Disorders; Mianserin; Middle Aged; Mirtazapine; Monoamine Oxidase Inhibitors; Moscow; Nootropic Agents; Olanzapine; Pharmacoepidemiology; Phenothiazines; Psychotropic Drugs; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Sulpiride | 2003 |
Are selective serotonin re-uptake inhibitors associated with an increased risk of self-harm by antidepressant overdose?
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Citalopram; Cyclohexanols; Doxepin; Drug Overdose; Drug Prescriptions; Emergency Service, Hospital; Female; Fluoxetine; Humans; Imipramine; Information Services; Male; Mianserin; Mirtazapine; Paroxetine; Patient Admission; Patient Readmission; Poison Control Centers; Retrospective Studies; Risk Assessment; Scotland; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Sertraline; Trazodone; Venlafaxine Hydrochloride | 2004 |
Effect of mirtazapine versus fluoxetine on "sleep quality".
Topics: Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder; Dose-Response Relationship, Drug; Fluoxetine; Humans; Mianserin; Mirtazapine; Research Design; Selective Serotonin Reuptake Inhibitors; Sleep; Sleep Initiation and Maintenance Disorders | 2004 |
Rapid screening of selective serotonin re-uptake inhibitors in urine samples using solid-phase microextraction gas chromatography-mass spectrometry.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Fluoxetine; Fluvoxamine; Gas Chromatography-Mass Spectrometry; Humans; Mianserin; Mirtazapine; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Sertraline; Solid Phase Microextraction; Venlafaxine Hydrochloride | 2005 |
Development of a solid phase extraction for 13 'new' generation antidepressants and their active metabolites for gas chromatographic-mass spectrometric analysis.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Cyclohexanols; Desvenlafaxine Succinate; Fluoxetine; Gas Chromatography-Mass Spectrometry; Humans; Mianserin; Microchemistry; Mirtazapine; Piperazines; Reproducibility of Results; Sertraline | 2005 |
Successful treatment of anorexia with a combination of high-dose olanzapine, fluoxetine and mirtazapine.
Topics: Adult; Anorexia; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; Fluoxetine; Humans; Mianserin; Mirtazapine; Olanzapine; Selective Serotonin Reuptake Inhibitors | 2006 |
An abbreviated version of the Connor-Davidson Resilience Scale (CD-RISC), the CD-RISC2: psychometric properties and applications in psychopharmacological trials.
Topics: Antidepressive Agents; Anxiety Disorders; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Kava; Mianserin; Mirtazapine; Paroxetine; Psychometrics; Sertraline; Stress Disorders, Post-Traumatic; Surveys and Questionnaires; Venlafaxine Hydrochloride | 2007 |
Geometric mean IELT and premature ejaculation: appropriate statistics to avoid overestimation of treatment efficacy.
Topics: Antidepressive Agents; Coitus; Data Interpretation, Statistical; Ejaculation; Fluoxetine; Fluvoxamine; Humans; Male; Mianserin; Mirtazapine; Models, Biological; Piperazines; Reaction Time; Research Design; Selective Serotonin Reuptake Inhibitors; Sensitivity and Specificity; Sertraline; Sexual Dysfunction, Physiological; Treatment Outcome; Triazoles | 2008 |
Antidepressant-associated mania: soon after switch from fluoxetine to mirtazapine in an elderly woman with mixed depressive features.
Topics: Adrenergic alpha-Antagonists; Aged; Bipolar Disorder; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Fluoxetine; Humans; Mianserin; Mirtazapine; Selective Serotonin Reuptake Inhibitors | 2009 |
Effect of antidepressants on body weight, ethology and tumor growth of human pancreatic carcinoma xenografts in nude mice.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Body Weight; Carcinoma; Cell Line, Tumor; Female; Fluoxetine; Male; Mianserin; Mice; Mice, Inbred BALB C; Mice, Nude; Mirtazapine; Neoplasm Transplantation; Pancreatic Neoplasms | 2008 |
Combining antidepressant medications: a good idea?
Topics: Antidepressive Agents; Bupropion; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Fluoxetine; Humans; Mianserin; Mirtazapine; Randomized Controlled Trials as Topic; Venlafaxine Hydrochloride | 2010 |
Loss of response after switching from brand name to generic formulations: three cases and a discussion of key clinical considerations when switching.
Topics: Drugs, Generic; Female; Fluoxetine; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Secondary Prevention; Therapeutic Equivalency; Valproic Acid | 2010 |
An audit to compare discharge rates between antidepressant monotherapies prescribed for pure unipolar depression versus depression in the presence of other indications.
Topics: Adult; Antidepressive Agents; Citalopram; Community Mental Health Centers; Comorbidity; Cyclohexanols; Depressive Disorder; England; Fluoxetine; Guideline Adherence; Humans; Medical Audit; Mianserin; Mirtazapine; Patient Discharge; Practice Patterns, Physicians'; Sertraline; Suicide; Suicide Prevention; Treatment Outcome; Venlafaxine Hydrochloride | 2010 |
Potentiation of omega-3 fatty acid antidepressant-like effects with low non-antidepressant doses of fluoxetine and mirtazapine.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Body Weight; Dose-Response Relationship, Drug; Drug Synergism; Fatty Acids, Omega-3; Fluoxetine; Male; Mianserin; Mirtazapine; Rats; Rats, Wistar; Swimming; Time Factors | 2010 |
Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers.
Topics: Affect; Amitriptyline; Animals; Antidepressive Agents; Antimanic Agents; Benzodiazepines; Cerebral Cortex; Citalopram; Clorgyline; Cocaine; Cyclohexanols; Desipramine; Fluoxetine; Imipramine; In Vitro Techniques; Iproniazid; Lithium; Mianserin; Mirtazapine; Mitochondria; Moclobemide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Morpholines; Olanzapine; Pargyline; Reboxetine; Swine; Thiazepines; Valproic Acid; Venlafaxine Hydrochloride | 2010 |
The effects of mirtazapine and fluoxetine on hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats.
Topics: Animals; Antidepressive Agents, Tricyclic; Disease Models, Animal; Fever; Fluoxetine; Male; Mianserin; Mirtazapine; N-Methyl-3,4-methylenedioxyamphetamine; Rats; Rats, Wistar; Serotonin 5-HT2 Receptor Antagonists; Serotonin Agents | 2011 |
Antidepressants differentially modify the extinction of an aversive memory task in female rats.
Topics: Animals; Antidepressive Agents; Anxiety; Avoidance Learning; Extinction, Psychological; Female; Fluoxetine; Maze Learning; Memory; Mianserin; Mirtazapine; Nortriptyline; Psychomotor Performance; Rats; Rats, Wistar | 2012 |
Simultaneous determination of 25 common pharmaceuticals in whole blood using ultra-performance liquid chromatography-tandem mass spectrometry.
Topics: Analgesics; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Chromatography, High Pressure Liquid; Clopenthixol; Fluoxetine; Histamine Antagonists; Humans; Limit of Detection; Linear Models; Methotrimeprazine; Methylphenidate; Mianserin; Mirtazapine; Pharmaceutical Preparations; Quality Control; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2012 |
Evaluation of the anti-ulcerogenic activity of the antidepressants duloxetine, amitriptyline, fluoxetine and mirtazapine in different models of experimental gastric ulcer in rats.
Topics: Amitriptyline; Animals; Anti-Ulcer Agents; Antidepressive Agents; Disease Models, Animal; Duloxetine Hydrochloride; Fluoxetine; Immersion; Indomethacin; Male; Mianserin; Mirtazapine; Rats; Rats, Sprague-Dawley; Reserpine; Restraint, Physical; Stomach Ulcer; Stress, Psychological; Thiophenes; Water | 2012 |
Influence of body mass index on the choice of therapy for depression and follow-up care.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Body Mass Index; Choice Behavior; Cohort Studies; Depression; Female; Fluoxetine; Follow-Up Studies; Humans; Logistic Models; Male; Mianserin; Middle Aged; Mirtazapine; Obesity; Paroxetine; Psychotherapy; Young Adult | 2013 |
Effect of co-treatment with fluoxetine or mirtazapine and risperidone on the active behaviors and plasma corticosterone concentration in rats subjected to the forced swim test.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Behavior, Animal; Corticosterone; Depression; Disease Models, Animal; Drug Interactions; Drug Therapy, Combination; Exploratory Behavior; Fluoxetine; Male; Mianserin; Mirtazapine; Motor Activity; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT1 Receptor Antagonists; Swimming | 2012 |
Human P-glycoprotein differentially affects antidepressant drug transport: relevance to blood-brain barrier permeability.
Topics: Amitriptyline; Animals; Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Blood-Brain Barrier; Capillary Permeability; Dogs; Duloxetine Hydrochloride; Fluoxetine; Humans; Imipramine; Madin Darby Canine Kidney Cells; Mianserin; Mirtazapine; Thiophenes; Transfection | 2013 |
Inhibitory effect of antidepressants on B16F10 melanoma tumor growth.
Topics: Animals; Antidepressive Agents; Cell Proliferation; Desipramine; Fluoxetine; Interleukin-10; Male; Melanoma, Experimental; Mianserin; Mice; Mice, Inbred C57BL; Mirtazapine; T-Lymphocytes; Tumor Cells, Cultured | 2013 |
Linking Clostridium difficile infection with depression.
Topics: Antidepressive Agents; Clostridioides difficile; Clostridium Infections; Depression; Fluoxetine; Humans; Mianserin; Mirtazapine; Risk Factors | 2013 |
Antidepressant action via the nitric oxide system: A pilot study in an acute depressive model induced by arginin.
Topics: Acute Disease; Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Arginine; Cyclopropanes; Depression; Fluoxetine; Male; Mianserin; Milnacipran; Mirtazapine; Nitric Oxide; Nitric Oxide Synthase; Pilot Projects; Rats, Wistar; Selective Serotonin Reuptake Inhibitors | 2015 |
Atypical antidepressants extend lifespan of Caenorhabditis elegans by activation of a non-cell-autonomous stress response.
Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Catalase; Fluoxetine; Histamine H1 Antagonists; Life Expectancy; Longevity; Mianserin; Mirtazapine; Oxidative Stress; Peroxiredoxins; Reactive Oxygen Species; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Superoxide Dismutase; Synaptic Transmission | 2015 |
Effects of anti-depressant treatments on FADD and p-FADD protein in rat brain cortex: enhanced anti-apoptotic p-FADD/FADD ratio after chronic desipramine and fluoxetine administration.
Topics: Adrenergic alpha-Antagonists; Animals; Antidepressive Agents; Apoptosis; Autoreceptors; Blotting, Western; Brain; CASP8 and FADD-Like Apoptosis Regulating Protein; Cerebral Cortex; Clorgyline; Desipramine; Electroshock; Excitatory Amino Acid Antagonists; Fas-Associated Death Domain Protein; Fluoxetine; Idazoxan; Indans; Ketamine; Male; Mianserin; Mirtazapine; Monoamine Oxidase Inhibitors; Norepinephrine Plasma Membrane Transport Proteins; Phenelzine; Phosphoproteins; Phosphorylation; Rats; RNA-Binding Proteins; Thiazoles | 2016 |
Repeated co-treatment with antidepressants and risperidone increases BDNF mRNA and protein levels in rats.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Citalopram; Drug Interactions; Fluoxetine; Frontal Lobe; Gene Expression Regulation; Hippocampus; Mianserin; Mirtazapine; Rats; Rats, Wistar; Risperidone; RNA, Messenger; Serotonin Antagonists | 2017 |
Discontinuation and dose adjustment of metoprolol after metoprolol-paroxetine/fluoxetine co-prescription in Dutch elderly.
Topics: Aged; Aged, 80 and over; Citalopram; Cohort Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Drug Prescriptions; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Metoprolol; Middle Aged; Mirtazapine; Netherlands; Paroxetine | 2018 |
Association of Antidepressant Use With Drug-Related Extrapyramidal Symptoms: A Pharmacoepidemiological Study.
Topics: Antidepressive Agents; Basal Ganglia Diseases; Bupropion; Case-Control Studies; Citalopram; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Pharmacoepidemiology; Sertraline; United States; Venlafaxine Hydrochloride | 2018 |
In-vitro and in situ assessment of the efflux of five antidepressants by breast cancer resistance protein.
Topics: Amitriptyline; Animals; Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biological Transport; Blood-Brain Barrier; Brain; Cell Line, Tumor; Duloxetine Hydrochloride; Fluoxetine; Humans; Mirtazapine; Neoplasm Proteins; Rats; Rats, Sprague-Dawley; Sertraline | 2019 |
Benefit of small dose antidepressants for functional dyspepsia: Experience from a tertiary center in eastern China.
Topics: Anthracenes; Antidepressive Agents; China; Citalopram; Drug Combinations; Dyspepsia; Female; Fluoxetine; Flupenthixol; Humans; Male; Middle Aged; Mirtazapine; Postprandial Period; Remission Induction; Retrospective Studies; Treatment Outcome | 2019 |
Molecular Consequences of Depression Treatment: A Potential In Vitro Mechanism for Antidepressants-Induced Reprotoxic Side Effects.
Topics: Amitriptyline; Animals; Antidepressive Agents; Antipsychotic Agents; Cell Line; Escitalopram; Fluoxetine; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation; Imipramine; Male; Mice; Micronuclei, Chromosome-Defective; Mirtazapine; Models, Biological; Olanzapine; Organ Specificity; Reboxetine; Reproduction; Signal Transduction; Spermatogenesis; Telomeric Repeat Binding Protein 1; Telomeric Repeat Binding Protein 2; Time Factors; Venlafaxine Hydrochloride | 2021 |
Stimulatory effect of fluoxetine and desipramine, but not mirtazapine on C26 colon carcinoma hepatic metastases formation: association with cytokines.
Topics: Animals; Antidepressive Agents; Carcinoma; Colonic Neoplasms; Cytokines; Desipramine; Fluoxetine; Liver Neoplasms; Male; Mice; Mirtazapine | 2023 |
Treatment-Resistant Depression (TRD): Is the Opioid System Involved?
Topics: Analgesics, Opioid; Animals; Antidepressive Agents; Depression; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Mianserin; Mice; Mirtazapine; Moclobemide; Naloxone; Reboxetine; Trazodone; Venlafaxine Hydrochloride | 2023 |
Simultaneous separation and determination of several chiral antidepressants and their enantiomers in wastewater by online heart-cutting two-dimensional liquid chromatography.
Topics: Antidepressive Agents; Bupropion; Chromatography, High Pressure Liquid; Fluoxetine; Mirtazapine; Stereoisomerism; Tandem Mass Spectrometry; Wastewater; Water Pollutants, Chemical | 2023 |